Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today we talk about Pfizer’s obesity woes, how J&J is leaning heavily into artificial intelligence, chat about how ADCs are having a heyday, and ponder the zombie microcap.
Pfizer’s GLP-1 troubles continue
Pfizer said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect